We’re experiencing issues for some mobile devices with our ARTG dataset filter function. We apologise for any inconvenience while we work to fix this.
Recently published
This page was published on [date_placeholder].
Recently updated
This page was updated on [date_placeholder]. See page history for details.
This guidance serves to inform sponsors and manufacturers on their post-market responsibilities for medical devices.
There are mandatory requirements and ongoing responsibilities for all manufacturers and sponsors of medical devices.
Despite premarket processes and risk mitigation, sometimes there are new issues that emerge over time.
The rationale behind ongoing responsibilities is to ensure information about emerging safety or risk-related issues is being recorded systematically, investigated per the manufacturer’s procedures, and reported to us when necessary.
Many of these incidents are required to be reported to the TGA to monitor the risk to public health and to patient safety, or to alert customers to newly identified hazards or changes in how the device may be used.
Information we receive about a device once it is included in the Australian Register of Therapeutic Goods (ARTG) informs actions including:
Sponsors play an important role in ensuring all products supplied in Australia continue to meet the regulatory requirements over time.
Sponsors are an important link in maintaining contact and exchanging information between the manufacturer of any devices they import, export or supply (hereafter referred to as supplied) and the TGA.
Sponsors are also required to work with the manufacturer and the TGA in making decisions and undertaking actions in relation to devices supplied, being supplied or intended to be supplied in Australia.
If you utilise suppliers or distributors for the on-selling of medical devices in Australia, you are also responsible for providing factual and up-to-date information to your supplier network about your devices, particularly if they are no longer included in the ARTG, or if there are any safety or recall related alerts that you need to communicate to customers and end users.
Where we receive signals, complaints or reports in relation to the safety, quality and performance of medical devices, we will aim to work closely with the sponsor to collect information about such signals, complaints or reports in the form of post-market reviews or the medical device incident reporting and investigations scheme (IRIS).
Where there are regulatory reforms or changes that may impact you, we will also communicate such changes to you.
You should continue refreshing your knowledge.
We continue to provide webinars, guidance and resources through our website, and we recommend all sponsors continue to remain actively engaged with the TGA and with their regulatory requirements.
The main requirements can be categorised as the following:
Failure to comply with ongoing responsibilities may result in the suspension or cancellation of your ARTG entries, the issuing of infringement notices, or criminal or civil penalties.
One major area of the sponsor ongoing responsibility is ensuring compliance with all conditions of inclusion for active ARTG entries.
All ARTG entries are subject to automatic conditions, and these are set out in section 41FN of the Act and detailed in the table below.
In addition to automatic conditions of inclusion, at times, ARTG entries are subject to additional conditions of inclusion.
Additional COIs may include providing one-off or periodic reports to the TGA to facilitate the ongoing monitoring of safety or performance data, or to report on known or potential risks, or restrictions on the device and their advertising/sale/use in a particular manner.
Additional COIs may be placed at the time of inclusion or at any time after the entry has been active, such as following a post-market review or investigation.
The sponsor will be notified in writing if there are specific conditions of inclusion relating to their entries.
Conditions may be imposed for a limited time period or may be ongoing.
Conditions may be varied and updated over time.
To comply with additional COIs, the sponsor must comply with each of the COIs as specified, which will often involve obtaining the relevant information from the manufacturer and providing it to the TGA within the required timeframes.
TGA does not routinely send reminders and compliance must be met within specified timeframes.
For additional COIs that include submission of periodic reports, it is the Sponsors responsibility to ensure that all reports are submitted by or before the due date outlined within that COI.
| Requirement | Example(s) | Legislative Reference |
|---|---|---|
| Allow entry and inspections of premises |
| Section 41FN(1) |
| Deliver samples upon request |
| Section 41FN(2) |
| Availability of information |
| Section 41FN(3) |
| Advertising material |
| Section 41FN(5) The Therapeutic Goods Advertising Code |
| Report details of certain incidents and performance issues to the TGA |
| Section 41FN(3)(d) Regulation 5.7 |
| Report results of investigations undertaken by the manufacturer to the TGA |
| Section 41FN |
| Assist the TGA and the manufacturer in investigations if an incident occurs |
| Section 41FN |
| Take corrective action when necessary |
| Section 41KA |
| Maintain distribution records for product supplied in or exported from Australia |
| Section 41FO Regulation 5.9, 5.10 Regulation 8.1(b) |
| Automatic Conditions apply when medical devices are included in the ARTG |
| Section 41FO(2) Regulation 5.11 |
The primary function of post-market monitoring and vigilance is to improve the health and safety of patients, health care professionals, users, and others by reducing the likelihood of adverse events.
Adverse event reporting allows us to monitor medical device use, their performance in the real world and identify trends that may indicate emerging safety and performance issues.
It is the responsibility of a manufacturer to investigate, have appropriate risk management procedures in place and take appropriate corrective and preventative actions in relation to their medical devices, in accordance with their conformity assessment procedures.
However, sponsors are required to report such events to us.
The reports allow us to review the manufacturer’s actions, and where required, take appropriate regulatory action to address these issues, thereby reducing the risks and impact on the public.
It is an automatic condition of inclusion under Part 5, Division 5.2, Clause 5.7 of the Therapeutic Goods (Medical Devices) Regulations 2002- external site that sponsors of a medical device report adverse events or near adverse events to IRIS.
Sponsors are able to submit these reports through the TGA eBusiness Portal.
It is important to note that the act of reporting a problem is not an admission of manufacturer, sponsor, user, or patient liability for the event or its consequences.
All adverse events of devices supplied in Australia are required to be reported to the TGA.
However, an adverse event that occurs in Australia for a device that was supplied or implanted in a country other than Australia, does not need to be reported to the TGA.
For more information, see Reporting adverse events for medical devices.
A market action is undertaken when therapeutic goods are, or may be, affected by a problem with their safety, quality, efficacy (medicines and biologicals), performance (medical devices) and presentation.
These problems may be due to non-compliance with specified standards or legislative or manufacturing requirements applicable to the therapeutic good.
The Procedure for recalls, product alerts and product corrections (PRAC) provides a consistent approach for undertaking market actions for therapeutic goods supplied, imported into or exported from Australia.
The purpose is to assist sponsors with conducting market actions using a standardised and systematic procedure.
It enables sponsors to respond efficiently and effectively to issues with a therapeutic good that has posed, or may pose, a risk to public health and safety.
The PRAC is also applicable when the TGA orders an appropriate responsible entity to conduct a mandatory recall.
It is of utmost importance that sponsors do not determine the type of market action to take without first going through the PRAC, notifying us and obtaining our agreement to proceed.
Sponsor should report any overseas regulatory actions to the TGA if the product involved is from the same batch or production run that was supplied in Australia.
The sponsor must ensure that any advertising of the medical device continues to comply with the current version of the Therapeutic Goods Advertising Code.
This applies for advertising of any format including print, online and social media.
Sponsors should also communicate to their suppliers and retailers about the TGA requirements of the Advertising Code, particularly about unauthorised claims of a therapeutic good.
In particular, the claim ‘TGA approved’ must not be used in advertising except with explicit TGA authorisation.
For more information, see Applying the Advertising Code rules.
Certain therapeutic claims are classified as restricted representations, and you must seek our approval before being able to advertise such claims to the general public.
There are ongoing annual charges associated with maintaining your inclusion in the ARTG.
The annual charge associated with your inclusion in the ARTG is available through the summary of fees and charges under 'Medical Devices' or 'IVD Medical Devices'.
Manufacturers have ongoing legal obligations for medical devices that they manufacture and are being supplied in Australia.
These obligations are outlined in full in the therapeutic goods legislation including:
As part of the approval process to supply a medical device in Australia, a manufacturer must hold appropriate evidence to demonstrate the application of the appropriate conformity assessment procedures, or requirements comparable to conformity assessment procedures.
The minimum requirements for a manufacturer will vary based on the classification of supplied devices and are specified in Part 3, Division 3.2 of the Regulations.
For some Class I devices, this requires signing an Australian Declaration of Conformity.
The Australian Declaration of Conformity states which conformity assessment procedures the manufacturer has chosen to use to demonstrate that their medical device meets the Essential Principles.
The ongoing obligations of a manufacturer vary depending on which conformity assessment procedures they have used.
In some instances, evidence of conformity from comparable overseas regulators can be used to demonstrate that Australian requirements are met.
These are assessed at the time of inclusion.
Evidence of conformity must be maintained and kept up to date.
Any changes, suspensions, revocations or lapses of conformity certificates must be notified to the Australian sponsor for notification to the TGA.
This evidence held by a manufacturer would be expected to include:
Note
If you only manufacture Class I devices you may not be subject to all of the above.An example is manufacturers of personal protective equipment (PPE).
As detailed in the conditions of inclusions (subsection 41FN(3) of the Act), a manufacturer is required to hold at all times evidence to demonstrate compliance with all applicable Essential Principles (EP).
If you have evidence of meeting essential requirements under the Europe MDR, you are expected to have performed a gap analysis to ensure requirements for all Australian EPs are met.
Under circumstances that prevent compliance of the device to the EPs, on a temporary basis, you must notify the sponsor who must then notify the TGA.
If the matter is not likely to result in significant safety issues, a consent process can be arranged via the Australian sponsor.
Unless covered by the exemption rules you must notify the TGA or the sponsor as soon as practicable after becoming aware of:
If you propose to make changes to products included in the ARTG, you also may need to work with the Australian sponsor to vary entries in the ARTG.
If any details on a TGA issued conformity assessment certificate is no longer correct, or you need to make a substantial change to certificates, you must also notify the TGA for changes to current certificates.
Updated content to include link to the Procedure for recalls, product alerts and product corrections (PRAC) | Therapeutic Goods Administration (TGA).
Title changed from 'Post market responsibilities for manufacturers and sponsors of medical devices' to 'Understanding your post-market responsibilities for medical devices' as part of migration to new 'Guidance' content type:
Major revision and update to content.
Reviewed foundation guidance document prior to guidance champion reviews.
Original publication.
Updated content to include link to the Procedure for recalls, product alerts and product corrections (PRAC) | Therapeutic Goods Administration (TGA).
Title changed from 'Post market responsibilities for manufacturers and sponsors of medical devices' to 'Understanding your post-market responsibilities for medical devices' as part of migration to new 'Guidance' content type:
Major revision and update to content.
Reviewed foundation guidance document prior to guidance champion reviews.
Original publication.
The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.
© Commonwealth of Australia
